Abstract
This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 365-368 |
| Number of pages | 4 |
| Journal | Blood Transfusion |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Keywords
- Bleeding
- Haemophilia A
- Inhibitors
- Obizur
- Porcine recombinant FVIII
ASJC Scopus subject areas
- Immunology and Allergy
- Hematology
Cite this
Porcine recombinant factor VIII : An additional weapon to handle anti-factor VIII antibodies. / Mannucci, Pier Mannuccio; Franchini, Massimo.
In: Blood Transfusion, Vol. 15, No. 4, 2017, p. 365-368.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Porcine recombinant factor VIII
T2 - An additional weapon to handle anti-factor VIII antibodies
AU - Mannucci, Pier Mannuccio
AU - Franchini, Massimo
PY - 2017
Y1 - 2017
N2 - This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.
AB - This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.
KW - Bleeding
KW - Haemophilia A
KW - Inhibitors
KW - Obizur
KW - Porcine recombinant FVIII
UR - http://www.scopus.com/inward/record.url?scp=85021818761&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021818761&partnerID=8YFLogxK
U2 - 10.2450/2016.0030-16
DO - 10.2450/2016.0030-16
M3 - Review article
AN - SCOPUS:85021818761
VL - 15
SP - 365
EP - 368
JO - Blood Transfusion
JF - Blood Transfusion
SN - 1723-2007
IS - 4
ER -